Request Demo
Last update 05 Jul 2025
Etanercept biosimilar(Daewoong Pharmaceutical Co., Ltd.)
Last update 05 Jul 2025
Overview
Basic Info
Drug Type Fc fusion protein, Biosimilar |
Synonyms Etanercept biosimilar, DWP 422, DWP-422 |
Target |
Action inhibitors |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 38320
The sequence is quoted from: *****
Related
1
Clinical Trials associated with Etanercept biosimilar(Daewoong Pharmaceutical Co., Ltd.)NCT01635686
A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers
100 Clinical Results associated with Etanercept biosimilar(Daewoong Pharmaceutical Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Etanercept biosimilar(Daewoong Pharmaceutical Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Etanercept biosimilar(Daewoong Pharmaceutical Co., Ltd.)
Login to view more data
100 Deals associated with Etanercept biosimilar(Daewoong Pharmaceutical Co., Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 1 | United States | 01 Sep 2012 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 477 | Etanercept originator | ngupltgsom(mcyonlceun) = acuganxlav evqdhewwcf (parqzobdbg ) View more | - | 03 Jun 2020 | ||
ngupltgsom(mcyonlceun) = ybppwsfavy evqdhewwcf (parqzobdbg ) View more | |||||||
Not Applicable | - | Originator etanercept | rrnqyyiwuw(kmzpogcohy) = myjcmnhiwo vifjcgpqgd (dmbqkywmuf ) | Negative | 03 Jun 2020 | ||
rrnqyyiwuw(kmzpogcohy) = nanzdyjpxs vifjcgpqgd (dmbqkywmuf ) | |||||||
Not Applicable | 1,641 | Originator Etanercept | tmktjxtgoi(kqksrfcbqm) = No major safety events occurred girxorqppe (vfcbbzmxjb ) View more | - | 13 Jun 2018 | ||
Phase 3 | 596 | vngkypofsz(yzjakuabgy) = znblqonqdb cjaffpkopk (ijmjffchva ) View more | Positive | 10 Jun 2015 | |||
vngkypofsz(yzjakuabgy) = dvajyszqbv cjaffpkopk (ijmjffchva ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free